RPG Life Sciences Limited (RPGLIFE.BO)
INR 2064.1
(4.69%)
INR 2064.1
(4.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.29 Billion INR | 26.99% |
| 2022 | 874.7 Million INR | 24.04% |
| 2021 | 705.2 Million INR | 41.81% |
| 2020 | 497.3 Million INR | 29.03% |
| 2019 | 385.4 Million INR | 166.53% |
| 2018 | 144.6 Million INR | -21.24% |
| 2017 | 183.6 Million INR | 44.57% |
| 2016 | 127 Million INR | 89.84% |
| 2015 | 66.9 Million INR | 12.63% |
| 2014 | 59.4 Million INR | 75.22% |
| 2013 | 33.9 Million INR | -52.32% |
| 2012 | 71.1 Million INR | -17.33% |
| 2011 | 86 Million INR | -63.79% |
| 2010 | 237.5 Million INR | 4.67% |
| 2009 | 226.9 Million INR | 34.06% |
| 2008 | 169.25 Million INR | -5.05% |
| 2007 | 178.25 Million INR | -17.13% |
| 2006 | 215.09 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 337.8 Million INR | 108.13% |
| 2023 Q1 | 280.3 Million INR | 133.19% |
| 2023 Q2 | 330.6 Million INR | 17.95% |
| 2023 FY | 1.11 Billion INR | 26.99% |
| 2023 Q4 | 162.3 Million INR | -51.93% |
| 2023 Q3 | 337.6 Million INR | 2.12% |
| 2022 Q3 | 253 Million INR | -2.17% |
| 2022 Q4 | 120.2 Million INR | -52.49% |
| 2022 FY | 874.7 Million INR | 24.04% |
| 2022 Q2 | 258.6 Million INR | 7.71% |
| 2022 Q1 | 240.1 Million INR | 146.76% |
| 2021 Q3 | 201.7 Million INR | -7.52% |
| 2021 FY | 705.2 Million INR | 41.81% |
| 2021 Q4 | 97.3 Million INR | -51.76% |
| 2021 Q1 | 189.9 Million INR | 110.07% |
| 2021 Q2 | 218.1 Million INR | 14.85% |
| 2020 Q1 | 131.4 Million INR | 281.98% |
| 2020 FY | 497.3 Million INR | 29.03% |
| 2020 Q4 | 90.4 Million INR | -47.53% |
| 2020 Q3 | 172.3 Million INR | 15.17% |
| 2020 Q2 | 149.6 Million INR | 13.85% |
| 2019 Q2 | 124 Million INR | 6.99% |
| 2019 FY | 385.4 Million INR | 166.53% |
| 2019 Q1 | 115.9 Million INR | 282.51% |
| 2019 Q4 | 34.4 Million INR | -68.06% |
| 2019 Q3 | 107.7 Million INR | -13.15% |
| 2018 Q4 | 30.3 Million INR | -63.23% |
| 2018 FY | 144.6 Million INR | -21.24% |
| 2018 Q3 | 82.4 Million INR | 98.55% |
| 2018 Q2 | 41.5 Million INR | 14.64% |
| 2018 Q1 | 36.2 Million INR | -30.65% |
| 2017 FY | 183.6 Million INR | 44.57% |
| 2017 Q4 | 52.2 Million INR | -41.55% |
| 2017 Q3 | 89.3 Million INR | 4.08% |
| 2017 Q2 | 85.8 Million INR | 500.0% |
| 2017 Q1 | 14.3 Million INR | -36.16% |
| 2016 Q1 | 84.2 Million INR | 236.8% |
| 2016 FY | 127 Million INR | 89.84% |
| 2016 Q3 | 20.7 Million INR | -53.38% |
| 2016 Q2 | 44.4 Million INR | -47.27% |
| 2016 Q4 | 22.4 Million INR | 8.21% |
| 2015 Q2 | 33.1 Million INR | 7.47% |
| 2015 Q1 | 30.8 Million INR | -41.78% |
| 2015 FY | 66.9 Million INR | 12.63% |
| 2015 Q3 | 52.2 Million INR | 57.7% |
| 2015 Q4 | 25 Million INR | -52.11% |
| 2014 Q4 | 52.9 Million INR | 49.01% |
| 2014 FY | 59.4 Million INR | 75.22% |
| 2014 Q1 | 15.2 Million INR | 168.47% |
| 2014 Q2 | -67.7 Million INR | -545.39% |
| 2014 Q3 | 35.5 Million INR | 152.44% |
| 2013 Q2 | 19.6 Million INR | 103.41% |
| 2013 FY | 33.9 Million INR | -52.32% |
| 2013 Q4 | -22.2 Million INR | 56.47% |
| 2013 Q3 | -51 Million INR | -360.2% |
| 2013 Q1 | -575.4 Million INR | -1144.28% |
| 2012 FY | 71.1 Million INR | -17.33% |
| 2012 Q2 | 22.5 Million INR | -50.33% |
| 2012 Q1 | 45.3 Million INR | 0.0% |
| 2012 Q4 | 55.1 Million INR | 225.51% |
| 2012 Q3 | -43.9 Million INR | -295.11% |
| 2011 FY | 86 Million INR | -63.79% |
| 2010 FY | 237.5 Million INR | 4.67% |
| 2009 FY | 226.9 Million INR | 34.06% |
| 2008 FY | 169.25 Million INR | -5.05% |
| 2007 FY | 178.25 Million INR | -17.13% |
| 2006 FY | 215.09 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 97.802% |
| NATCO Pharma Limited | 25.96 Billion INR | 91.171% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 50.25% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -819.675% |
| Achyut Healthcare Limited | 4.43 Million INR | -51551.645% |
| Ajanta Pharma Limited | 19.67 Billion INR | 88.351% |
| Alkem Laboratories Limited | 19.46 Billion INR | 88.222% |
| Alpa Laboratories Limited | 184.49 Million INR | -1142.459% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 60.19% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -33.467% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 94.568% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -86.214% |
| Brooks Laboratories Limited | 14.44 Million INR | -15774.654% |
| Divi's Laboratories Limited | 33.08 Billion INR | 93.07% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 96.615% |
| Eris Lifesciences Limited | 5.18 Billion INR | 55.762% |
| FDC Limited | 2.98 Billion INR | 23.237% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 64.747% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 74.471% |
| Granules India Limited | 6.81 Billion INR | 66.372% |
| Gufic Biosciences Limited | 1.32 Billion INR | -72.365% |
| Hester Biosciences Limited | 364.81 Million INR | -528.354% |
| Indoco Remedies Limited | 1.29 Billion INR | -77.347% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 48.144% |
| Ipca Laboratories Limited | 7.98 Billion INR | 71.277% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -351.125% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 1608.519% |
| Lasa Supergenerics Limited | -458 Million INR | 600.497% |
| Laurus Labs Limited | 3.94 Billion INR | 41.947% |
| Lupin Limited | 28.04 Billion INR | 91.826% |
| Mankind Pharma Limited | 21.51 Billion INR | 89.347% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -2185.444% |
| Megasoft Limited | -121.1 Million INR | 1992.836% |
| Piramal Pharma Limited | 4.55 Billion INR | 49.696% |
| Sigachi Industries Limited | 1.47 Billion INR | -55.527% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 155.705% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -302.358% |
| Windlas Biotech Limited | 1.29 Billion INR | -76.481% |
| ZIM Laboratories Limited | 253.82 Million INR | -803.088% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 94.682% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 17.721% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -401.001% |
| Bal Pharma Limited | 233.9 Million INR | -879.996% |
| Strides Pharma Science Limited | 5.22 Billion INR | 56.135% |
| Venus Remedies Limited | 534.65 Million INR | -328.747% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 26.719% |
| Nectar Lifesciences Limited | 923.8 Million INR | -148.137% |
| Shilpa Medicare Limited | 1.36 Billion INR | -67.778% |
| Aarti Drugs Limited | 7.14 Billion INR | 67.934% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -43.556% |
| Suven Life Sciences Limited | -1.22 Billion INR | 287.001% |
| Ind-Swift Limited | 1.22 Billion INR | -86.979% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 83.951% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 159.495% |
| Themis Medicare Limited | 392.58 Million INR | -483.893% |
| Hikal Limited | 32.11 Million INR | -7038.898% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 90.952% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -265.89% |
| Wockhardt Limited | -670 Million INR | 442.134% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 55.824% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -25177.052% |
| Neuland Laboratories Limited | 5.31 Billion INR | 56.896% |
| Morepen Laboratories Limited | 4.17 Billion INR | 45.079% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1001.802% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -8248.387% |